PlantForm Corporation

PlantForm's mission is to provide low-cost biosimilar antibody drugs to help people fight cancer and other critical illnesses.

Antibody therapies are revolutionizing how we treat disease. The problem is that the drugs now on the market are also extremely expensive. Access to more affordable alternatives is a priority for patients, health-care providers and insurers.

PlantForm's proprietary, plant-based technology platform was developed at the University of Guelph by Dr. Chris Hall, the Canada Research Chair in Recombinant Antibody Technology.

This platform — protected with patent filings — is designed to allow PlantForm to produce fully active versions of approved antibody drugs for as little as five per cent of the manufacturing cost of brand-name products.

Fighting breast cancer: Our first product will be a biosimilar (generic) version of the breast-cancer drug Herceptin, the brand name for trastuzumab.

We also plan to develop and produce biosimilar versions of three other cancer drugs that, together with Herceptin, had combined annual global sales of $23.1 billion in 2009.